Sage Announces Presentation Of Analyses From Clinical Program Of Zuranolone In MDD

Sage Therapeutics Inc. (SAGE) and Biogen Inc. (BIIB) said that new analyses from the landscape clinical development program of zuranolone in major depressive disorder or MDD were presented at the American College Of Neuropsychopharmacology Congress.

Data from the SHORELINE and WATERFALL Studies in the LANDSCAPE clinical program provided further the understanding of the potential efficacy and safety profile of zuranolone for the treatment of major depressive disorder.

According to the companies, patients receiving zuranolone 50 mg in the WATERFALL Study demonstrated rapid improvements in depressive and anxiety symptoms, as early as the first measured timepoint (Day 3 for HAMD-17 and Day 8 for HAM-A), with average improvements maintained through the end of the study (Day 42).

The companies noted that safety data from the WATERFALL study was consistent with the zuranolone safety profile seen to date across the LANDSCAPE program.

The company stated that Zuranolone was generally well-tolerated in a subgroup of patients aged 65 years and older in the SHORELINE Study, showing similar efficacy and safety results in the datasets analyzed to that observed in the general study population.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MTD Products Inc. is recalling 1,774 units of walk-behind self-propelled lawn mowers for potential risk of fire hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the lawn mower can leak fuel when it is stored in the upright (vertical) storage position to pose a fire hazard. Nike Inc. announced its plans to exit the Russian market completely following Russia's ongoing war against Ukraine, reports said. The sportswear major, with more than 100 stores in the country, had suspended operations there in March. Earlier in March, while suspending operations temporarily, the company had said its customers that it couldn't guarantee product shipments. The U.S. Food and Drug Administration unveiled its action plan to advance drug development for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis or ALS, in five years. The FDA plans specific actions such as regulatory science initiatives, enhancements to existing programs and new policy initiatives for the purpose. It will use public-private partnerships...
Follow RTT